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To the Editor
We very much appreciate the perspective of Dr. Lampman regarding our recent publication
in Arthritis and Rheumatology, titled “Disrupted brain circuitry for pain-related reward/
punishment in fibromyalgia”(1). In biomedicine, and indeed most experimental sciences, the
choice of a proper control group (or condition) is a fundamental step to ensure that the
conclusions drawn from an experiment have validity and are meaningful.
What is a proper control in a fibromyalgia study? The answer is, of course, “it depends on
what question is being investigated”. In our recent study, we used functional magnetic
resonance imaging to test the hypothesis that fibromyalgia patients demonstrate altered brain
activity during anticipation of pain and of relief. For this experiment, we elected to compare
the fibromyalgia patients to pain-free healthy volunteers, rather than a different “diseased
control group” (such as a group with a different pain disorder). In the Letter to the Editor by
Lampman, this choice was criticized because our approach, it was argued, prevented us from
assessing whether the observed alterations in brain activity are unique to fibromyalgia (or
could be observed in other pain conditions, such as “pain-causing disorders known to be
peripheral and nociceptive”).
We would like to point out that the purpose of our study was never to identify brain
alterations specific to fibromyalgia, and we never made such a claim in the manuscript.
Rather, our aim was to demonstrate in fibromyalgia patients the presence of alterations from
the healthy brain (which may or may not be unique to this particular chronic pain disorder).
For this purpose, we believe that the choice of a demographically-matched control group of
healthy volunteers was entirely appropriate. Future experiments will need to assess whether
a similar paradigm applied to the study of other chronic pain disorders, with greater or lesser
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peripheral or nociceptive pain components, yields similar results or not. Indeed, a newly-
proposed pain taxonomy (2) provides a number of categories of chronic pain conditions, and
it would certainly be instructive to compare fibromyalgia patients to samples of patients with
localized peripheral or central neuropathic pain conditions, visceral pain syndromes, cancer-
related pain, regional musculoskeletal pain disorders, etc.
We certainly agree that our fibromyalgia and control groups did not differ only for the
presence or absence of widespread pain, but also in terms of other factors (negative affect,
fatigue, etc). These differences, however, are truly reflective of the multisymptom nature of
fibromyalgia and we do not believe are ‘confounds’ in our experimental design. Symptoms
such as fatigue, anxiety, depression, sleep and cognitive deficits are highly comorbid with,
and therefore an integral part of, fibromyalgia (3, 4). Attempting to identify a control group
that is perfectly matched to the fibromyalgia group, except for the presence of pain, would
not only be extremely difficult, but also would generate results that would not reflect the full
spectrum of the fibromyalgia disorder. On the other hand, we agree that it is important to try
to determine whether any specific symptoms reported by fibromyalgia patients contribute
more than others to explain any differences in brain processing observed. Such an analysis
requires a multivariate statistical approach in a large patient sample, and we hope that future
analyses will in fact be able to tease out the distinct contributions of different variables to
the neuroimaging alterations reported in previous studies.
Finally, as for the large range in clinical pain reported by our patients, we feel that this is
endemic to the fibromyalgia population and may be advantageous for dynamic range in
further statistical analyses, something we will take full advantage of in future analyses
exploring the relationship between pain levels and brain activity.
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